Clinical Trials for Addiction Treatment: A Family's Guide to Finding and Joining One

When a family has already tried an outpatient program, a detox, and a residential stay, the questions stop being about logistics and turn into something harder: what is actually left to try? For a smaller number of families than you would guess — but a real number — the answer is a clinical trial.

A trial is not a charity program and not a shortcut into a better rehab. It is a research study, which means it comes with rules, uncertainty, and paperwork. It also means something genuinely different: access to a treatment that is not yet available any other way, usually at no cost for the study-related care, and often with more clinical attention than routine treatment provides.

This guide walks through what addiction trials are, how to find one that is actually recruiting, what you are legally entitled to before anyone signs anything, what trials do and do not pay for, and how to tell a real study from a sales pitch.

What a clinical trial is — and what it is not

The FDA defines clinical trials as research studies involving human volunteers that evaluate medical products — medications, vaccines, or devices — for safety and effectiveness. The purpose is to answer a specific research question. That is a different goal from treating one person well, and the difference matters when you are deciding whether to enroll.

A few consequences follow from that definition:

A trial is research first. The people running it are trying to produce a reliable answer, which is why the rules about who can join are so rigid and why randomization exists.
A registry listing is not an endorsement. NIDA is explicit about this: a study appearing on ClinicalTrials.gov does not mean the U.S. federal government has evaluated or approved it. Anyone can see the listing; that is the point of a public registry.
"Clinical research" is broader than "trial." Some studies simply observe people over time without offering any treatment at all. Those can still be valuable, but they are not a route to a new medication, and they usually pay nothing beyond a small amount for your time.

The three kinds of studies you will actually see

1. Medication trials

These test a drug — a new compound, a new use for an approved drug, a long-acting injectable, or a combination of existing medications. They are the studies families usually mean when they say "a trial," and they go through numbered phases: early phases focus on safety and dosing, later phases on whether the treatment actually works compared with something else.

As of October 13, 2026, ClinicalTrials.gov listed 115 recruiting studies for substance use disorder in Phase 2 or Phase 3 — the later-stage studies that are closest to becoming real treatment options.

2. Behavioral, counseling, and digital trials

These test a way of delivering care rather than a chemical: a therapy protocol, a peer-support model, a smartphone program, or a telehealth format. Contingency management — the incentive-based approach that NIDA describes as the best-studied behavioral treatment for stimulant use — is often studied this way. In the same snapshot, 25 recruiting studies matched contingency management.

A practical note for families: ask what each study arm actually is. A well-run behavioral trial usually compares a new approach against the best current standard, which is a better arrangement for a participant than a comparison against nothing.

3. Psychedelic-assisted trials

Psilocybin, ibogaine, and related compounds are being studied for addiction in regulated research settings. These are investigational — they are not available as clinical treatment outside a study, and any clinic offering them as routine care should be treated with caution. In the same snapshot, 15 recruiting studies matched psilocybin.

Why a family would consider a trial

The FDA lists three reasonable reasons to join a study: you and your health care provider believe a trial may offer another option when standard treatments have not worked; you want to help test new treatments; and you want to help researchers find better ways to fight disease. All three apply in addiction, and one more does too.

It can be the only door to something new. For opioid use disorder there are three FDA-approved medications. For alcohol use disorder there are approved options. For stimulant use disorder there are none — NIDA states plainly that there is no FDA-approved medication for methamphetamine use disorder or any other stimulant use disorder. A trial is the only route to a medication for that condition until one is approved.
Study-related care is usually free to the participant. NIDA's guidance says there is no charge for study-related medical care such as study visits, medicines, or procedures, and that a trial may also pay for transportation or other costs. For a family that has drained savings on treatment, that is not a small thing.
Monitoring tends to be closer than ordinary care. Trial participants are assessed on a schedule, with labs and check-ins built into the protocol.
Underrepresentation is a real problem, and joining is a response to it. The FDA notes that people from underserved communities are underrepresented in clinical research, and that participants should represent the patients who will eventually use these treatments.

The honest downsides

You may not get the new treatment. Randomization means assignment by chance.
Some studies use a placebo. Others compare against standard care. You are entitled to know which — see below.
The schedule is the schedule. Visits, blood draws, and questionnaires can run for months, and they are not negotiable the way a normal appointment is.
Distance is a genuine barrier. A study can be excellent and still be four hours away.
Rules can conflict with current prescriptions. Stability requirements sometimes mean changing medication under supervision, or waiting a set period after last use.
A trial is not a substitute for treatment. It sits alongside evidence-based care, never instead of it.

How to search the registry without getting lost

ClinicalTrials.gov is the public registry the FDA and NIDA both point families to. A short, deliberate search beats a broad one:

Go to clinicaltrials.gov and search the condition by name — "opioid use disorder," "alcohol use disorder," "stimulant use disorder" — rather than by a drug name.
Open the Status filter and check Recruiting. NIDA's own walkthrough recommends exactly this: check the Recruiting box and apply the filters so you only see studies currently looking for participants.
Narrow by location — country, state, and a radius around your ZIP code — then by age, then by study type if you only want studies that offer an intervention.
Open the records that survive. The Eligibility Criteria box is the single most important field on the page; read it before you get attached to a study.
Read Last Update Posted to see how current the record is, and the Locations field to see whether there is a site near you rather than just a sponsor's address.

Then do the thing most families skip: use the Contacts and Locations entry to email the study coordinator. A coordinator — not the front desk of a hospital — is the person who can tell you in one reply whether your relative is plausibly eligible. Ask whether there is a screening visit, what it involves, and what happens if the study is full.

What is actually recruiting right now

Numbers change daily, and that is exactly why they are useful: they show you the size and shape of the research landscape rather than one family's bad luck. On October 13, 2026, a query of the ClinicalTrials.gov public API for the condition "substance use disorder" returned:

653 recruiting studies in total
584 of them interventional studies that actually offer a treatment, medication, or program
508 with at least one location in the United States, 471 of those interventional
115 in Phase 2 or Phase 3
236 more registered as not yet recruiting

Broken down by condition, recruiting studies were:

Opioid use disorder: 237
Alcohol use disorder: 234
Cannabis use disorder: 74
Stimulant use disorder: 24

That last figure is the one worth sitting with. Stimulant use disorder has the fewest recruiting studies of any major substance category and no FDA-approved medication — which is why a stimulant trial is often the only path to a medication at all.

Read these numbers the way a researcher would. The count is a snapshot, not a promise. A listing is not an endorsement. And a large share of those 653 studies will exclude any given person for reasons that have nothing to do with how much help they need.

Who gets in, and why the rules are so strict

Eligibility criteria typically cover:

Diagnosis — the study enrolls a specific condition, sometimes a specific severity.
Age and sex — some protocols enroll only adults, some only post-menopausal women, some only people who are not pregnant or who agree to contraception.
Medication status — many trials require a person to be stable on their current medication, or off a substance for a defined period before screening.
Psychiatric and medical stability — active suicidality, unstable liver or heart disease, or certain interacting prescriptions are common exclusions, for safety rather than judgment.
Geography and commitment — the ability to attend visits on schedule is a criterion like any other.

If your relative is screened out, do not stop there. Ask the coordinator three questions: is this exclusion permanent or protocol-specific; are there other studies at this site looking for a different profile; and would it be worth re-screening after a period of stability. A "not yet recruiting" study is also an option worth putting on a calendar.

One boundary families need to hear clearly: an adult enrolls themselves. The regulations require the informed consent of the subject or the subject's legally authorized representative, which is the route when someone lacks capacity — but a study cannot take an unwilling adult because a family member signed for them. The same regulation requires consent to be sought under circumstances that minimize the possibility of coercion or undue influence. If you are considering pressure, that is your signal to stop and talk to a clinician instead.

Placebo, randomization, and the question every family asks

Yes, some trials use a placebo. Yes, some participants do not receive the new treatment. The important part is what the study is obliged to tell you.

The federal consent rule requires the document to describe the procedures to be followed and identify which of them are experimental; to describe reasonably foreseeable risks and discomforts; to describe expected benefits; and to disclose appropriate alternative procedures or courses of treatment that might be advantageous to you. In plain language: if buprenorphine or methadone is a real option for your relative, a legitimate trial must tell you so rather than implying it is the study or nothing.

So ask, in writing, before anyone signs: does this study use a placebo; what do participants in the comparison group receive; what happens if the treatment is clearly not working; and will we be told the results when the study ends.

What you are entitled to before you sign

Before you agree to join, the FDA says the study will be explained to you in an informed consent process. Under the federal rule that governs most human-subjects research, that consent must include all of the following:

A statement that the study involves research, its purposes, the expected duration of participation, the procedures involved, and which procedures are experimental.
A description of reasonably foreseeable risks or discomforts.
A description of any benefits reasonably expected, to the participant or to others.
Disclosure of appropriate alternative treatments.
A statement of the extent to which confidentiality of records will be maintained.
An explanation of whether compensation and medical treatment are available if injury occurs.
Names of whom to contact with questions about the research and about participants' rights.
A statement that participation is voluntary, that refusal involves no penalty or loss of benefits, and that the participant may stop at any time without penalty or loss of benefits.

Three further protections are worth knowing. The information must be given in language understandable to the person consenting. Consent must begin with a concise, focused presentation of the key information, not a wall of text. And no consent document may contain language through which a participant waives, or appears to waive, any legal right or releases the researchers from liability for negligence.

Every study is also reviewed and overseen by an institutional review board. If nobody in the program can tell you which IRB approved the study, that is a problem, not a technicality.

Money: what a trial pays for, and what it does not

NIDA's guidance is the clearest benchmark for families. There is generally no charge for study-related medical care — study visits, study medicines, and study procedures — and a trial may cover transportation or other costs.

What that does not mean:

A trial will not cover rent, childcare, or lost wages beyond whatever the protocol states.
Care that falls outside the study may still be billed to insurance.
Compensation for time and travel varies widely from study to study — common in some, absent in others.
Observational studies usually offer no treatment and minimal compensation.

Read the costs and compensation section of the consent document carefully, and ask for anything unclear to be put in writing. If the barrier is money rather than research, our guides on paying for treatment without insurance and appealing an insurance denial cover the other routes.

Red flags: when a "trial" is a sales pitch

Most research programs are honest and administratively careful. The signals of something else are specific:

No consent document, or a "consent" that is a one-page intake form.
Nobody can name the review board that oversees the study.
Cash or a card requested up front for a bed, framed as study participation.
A guarantee of the active treatment — that is not how randomization works.
An offer to enroll your adult relative on your signature, without that person's own consent.
A consent form containing a liability waiver. Language that appears to waive legal rights is prohibited outright.
A substance offered as a "trial" with no protocol number, no sponsor, and no registry entry.

If any of those appear, walk away. Then check the registry yourself — a genuine study is normally registered, and the record will name a sponsor and contacts you can verify independently.

Trials sit alongside treatment, not instead of it

However promising a study looks, standard evidence-based care remains the baseline. For opioid use disorder that means methadone, buprenorphine, or naltrexone; for alcohol use disorder there are approved medications as well as behavioral treatment; for stimulant use disorder the strongest evidence is behavioral, with contingency management leading. Our guides on medication-assisted treatment and evidence-based therapies go through those options in detail, and the stimulant treatment guide covers what works when no medication is approved yet.

If someone is in crisis today — an overdose, withdrawal that looks dangerous, or talk of suicide — that is a 988 or 911 call, not a research question. The overdose response guide and the naloxone guide cover what to do first.

Where to get help and information now

988 Suicide and Crisis Lifeline — call or text 988, free and available 24/7.
911 — for an overdose, a seizure, breathing difficulty, or any medical emergency.
SAMHSA National Helpline — 1-800-662-4357, free, confidential, 24/7, English and Spanish, for treatment referrals and information.
FindTreatment.gov — SAMHSA's treatment locator, searchable by ZIP code and payment type.
Poison Control — 1-800-222-1222 for a possible poisoning or bad reaction.
NIDA study questions — (800) 535-8254, for questions about study participation, privacy, and what to expect at screening in NIDA studies.
ClinicalTrials.gov — the registry itself; search by condition and check the Recruiting filter.

What to do this week

Write down the diagnosis as a clinician states it, plus every medication your relative currently takes. You will need both for any screening call.
Search the registry for that condition with the Recruiting filter on, and filter to your state.
Email or call two study coordinators, not ten. Ask whether your relative is plausibly eligible before you invest emotionally.
Ask your relative's own clinician to review the top candidate study with you — the FDA recommends exactly that conversation.
Ask for the consent document in advance and read the alternatives, risks, and costs sections before the screening visit.
Keep standard treatment in place while you explore. A trial is an addition, not a replacement.

The bottom line

Clinical trials are not a last resort and not a lottery ticket. They are a defined, regulated route to treatments that do not yet exist on a pharmacy shelf — free of charge for study-related care, closely monitored, and bound by consent rules that give the participant real rights, including the right to walk away at any time. For families dealing with stimulant use disorder, where no medication is approved at all, and for anyone whose standard options have genuinely been exhausted, a recruiting trial deserves a serious look rather than a shrug.